JP5504259B2 - 第ｉｘａ因子阻害剤としての複素環式化合物 - Google Patents
第ｉｘａ因子阻害剤としての複素環式化合物 Download PDFInfo
- Publication number
- JP5504259B2 JP5504259B2 JP2011510610A JP2011510610A JP5504259B2 JP 5504259 B2 JP5504259 B2 JP 5504259B2 JP 2011510610 A JP2011510610 A JP 2011510610A JP 2011510610 A JP2011510610 A JP 2011510610A JP 5504259 B2 JP5504259 B2 JP 5504259B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- phenyl
- aryl
- group
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 Bc1cc(-c([n]nc2C3=NC4=CC=C(*)CC4N3)c2O)ccc1 Chemical compound Bc1cc(-c([n]nc2C3=NC4=CC=C(*)CC4N3)c2O)ccc1 0.000 description 22
- BOZNWXQZCYZCSH-UHFFFAOYSA-N CCOC(CC(Cc1ccccc1)=O)=O Chemical compound CCOC(CC(Cc1ccccc1)=O)=O BOZNWXQZCYZCSH-UHFFFAOYSA-N 0.000 description 2
- UREFQWKAWKPMHK-UHFFFAOYSA-N Bc1cc(-c([nH]nc2-c([nH]c3c4)nc3ccc4OC)c2O)ccc1 Chemical compound Bc1cc(-c([nH]nc2-c([nH]c3c4)nc3ccc4OC)c2O)ccc1 UREFQWKAWKPMHK-UHFFFAOYSA-N 0.000 description 1
- SHZUGAIDQSTBNV-DAXSKMNVSA-N CC/C=C\C(C)Nc1nc(cccc2)c2[nH]1 Chemical compound CC/C=C\C(C)Nc1nc(cccc2)c2[nH]1 SHZUGAIDQSTBNV-DAXSKMNVSA-N 0.000 description 1
- IQHGJRGITYTCTQ-UHFFFAOYSA-N CC1C(c2c(C(Nc3cc(C#N)ccc3N)=C)[n](C)nc2C2=CC=CCC2)=C1 Chemical compound CC1C(c2c(C(Nc3cc(C#N)ccc3N)=C)[n](C)nc2C2=CC=CCC2)=C1 IQHGJRGITYTCTQ-UHFFFAOYSA-N 0.000 description 1
- XHSQCGLIUHLCAD-UHFFFAOYSA-N C[n](c(-c([nH]c1c2)nc1ccc2C(N)=O)c1OC)nc1-c1cccc(C=C)c1 Chemical compound C[n](c(-c([nH]c1c2)nc1ccc2C(N)=O)c1OC)nc1-c1cccc(C=C)c1 XHSQCGLIUHLCAD-UHFFFAOYSA-N 0.000 description 1
- WZPGFBGFZJDUER-UHFFFAOYSA-N C[n](c(C(Nc1ccc(CN)cc1)=O)c1O)nc1-c1ccccc1 Chemical compound C[n](c(C(Nc1ccc(CN)cc1)=O)c1O)nc1-c1ccccc1 WZPGFBGFZJDUER-UHFFFAOYSA-N 0.000 description 1
- NKKLRMMAYONDOZ-UHFFFAOYSA-N C[n](c(C(O)=O)c1OC)nc1-c1ccccc1 Chemical compound C[n](c(C(O)=O)c1OC)nc1-c1ccccc1 NKKLRMMAYONDOZ-UHFFFAOYSA-N 0.000 description 1
- JJEFSCCZZCCHEF-UHFFFAOYSA-N Cc(cc1)ccc1-c1n[nH]c(C(OC)=O)c1O Chemical compound Cc(cc1)ccc1-c1n[nH]c(C(OC)=O)c1O JJEFSCCZZCCHEF-UHFFFAOYSA-N 0.000 description 1
- DJMBYVYUJWTSLY-UHFFFAOYSA-N Cc(cc1)ccc1-c1n[n](C)c(-c2nc3cc(CNC)ccc3[nH]2)c1O Chemical compound Cc(cc1)ccc1-c1n[n](C)c(-c2nc3cc(CNC)ccc3[nH]2)c1O DJMBYVYUJWTSLY-UHFFFAOYSA-N 0.000 description 1
- UZAODEKUFLYINX-UHFFFAOYSA-N Cc1ccc2nc(-c([n](C)nc3-c4ccccc4)c3O)[nH]c2c1 Chemical compound Cc1ccc2nc(-c([n](C)nc3-c4ccccc4)c3O)[nH]c2c1 UZAODEKUFLYINX-UHFFFAOYSA-N 0.000 description 1
- VMZCDNSFRSVYKQ-UHFFFAOYSA-N O=C(Cc1ccccc1)Cl Chemical compound O=C(Cc1ccccc1)Cl VMZCDNSFRSVYKQ-UHFFFAOYSA-N 0.000 description 1
- FUIIOTCIPMDQJB-UHFFFAOYSA-N Oc(cc1)cc2c1nc(C1=C=CCNC(c3ccccc3)=C1O)[nH]2 Chemical compound Oc(cc1)cc2c1nc(C1=C=CCNC(c3ccccc3)=C1O)[nH]2 FUIIOTCIPMDQJB-UHFFFAOYSA-N 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N c1ccccc1 Chemical compound c1ccccc1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5431008P | 2008-05-19 | 2008-05-19 | |
| US61/054,310 | 2008-05-19 | ||
| PCT/US2009/044291 WO2009143039A2 (en) | 2008-05-19 | 2009-05-18 | Heterocyclic compounds as factor ixa inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011520967A JP2011520967A (ja) | 2011-07-21 |
| JP2011520967A5 JP2011520967A5 (enExample) | 2012-06-07 |
| JP5504259B2 true JP5504259B2 (ja) | 2014-05-28 |
Family
ID=41066042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011510610A Expired - Fee Related JP5504259B2 (ja) | 2008-05-19 | 2009-05-18 | 第ｉｘａ因子阻害剤としての複素環式化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8148363B2 (enExample) |
| EP (2) | EP2300435A2 (enExample) |
| JP (1) | JP5504259B2 (enExample) |
| CN (1) | CN102099340A (enExample) |
| AR (1) | AR071823A1 (enExample) |
| CA (1) | CA2724430A1 (enExample) |
| CL (1) | CL2009001214A1 (enExample) |
| MX (1) | MX2010012635A (enExample) |
| PE (1) | PE20091972A1 (enExample) |
| TW (1) | TW201008930A (enExample) |
| WO (1) | WO2009143039A2 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA33451B1 (fr) * | 2009-06-26 | 2012-07-03 | Novartis Ag | Dérivés d'imidazolidin-2-one 1,3-disubstitués en tant qu'inhibiteurs de cyp 17 |
| US8242284B1 (en) * | 2009-09-21 | 2012-08-14 | The United States Of America As Represented By The United States Department Of Energy | Anti-cancer agents based on 6-trifluoromethoxybenzimidazole derivatives and method of making |
| JP6155187B2 (ja) * | 2010-03-30 | 2017-06-28 | ヴァーセオン コーポレイション | トロンビンの阻害剤としての多置換芳香族化合物 |
| ES2626601T3 (es) * | 2010-06-28 | 2017-07-25 | Bayer Intellectual Property Gmbh | Compuestos heterocíclicos como pesticidas |
| WO2012003405A1 (en) | 2010-06-30 | 2012-01-05 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| NZ609955A (en) | 2010-11-09 | 2015-05-29 | Ironwood Pharmaceuticals Inc | Sgc stimulators |
| EA023064B1 (ru) | 2011-04-28 | 2016-04-29 | Новартис Аг | ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ |
| EP2729150B1 (en) | 2011-07-08 | 2016-09-14 | Merck Sharp & Dohme Corp. | Factor ixa inhibitors |
| ES2882807T3 (es) | 2011-09-16 | 2021-12-02 | Novartis Ag | Heterociclil carboxamidas N-sustituidas |
| CN104066731B (zh) | 2011-12-27 | 2016-06-15 | 铁木医药有限公司 | 可用作sgc刺激剂的2-苄基、3-(嘧啶-2-基)取代的吡唑类 |
| CN102660253B (zh) * | 2012-03-07 | 2014-05-21 | 泰山医学院 | 一种吡唑啉衍生物类Ni2+荧光探针及其应用 |
| US9914727B2 (en) | 2012-12-19 | 2018-03-13 | Merck Sharp & Dohme Corp. | Factor IXa inhibitors |
| US9695198B2 (en) | 2012-12-19 | 2017-07-04 | Merck Sharp & Dohme Corp. | Factor IXa inhibitors |
| EP2934538B1 (en) * | 2012-12-19 | 2021-03-31 | Merck Sharp & Dohme Corp. | Factor ixa inhibitors |
| ES2791749T3 (es) | 2013-03-15 | 2020-11-05 | Verseon Corp | Halogenopirazoles como inhibidores de la trombina |
| WO2014145986A1 (en) | 2013-03-15 | 2014-09-18 | Verseon, Inc. | Multisubstituted aromatic compounds as serine protease inhibitors |
| WO2015160636A1 (en) | 2014-04-16 | 2015-10-22 | Merck Sharp & Dohme Corp. | Factor ixa inhibitors |
| US10266526B2 (en) * | 2014-09-10 | 2019-04-23 | Epizyme, Inc. | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer |
| WO2016044645A1 (en) * | 2014-09-17 | 2016-03-24 | Elmaleh David R | Anticoagulant derivatives for cardiovascular imaging |
| KR20170048410A (ko) | 2014-09-17 | 2017-05-08 | 베르선 코포레이션 | 세린 프로테아제 저해제로서의 피라졸릴-치환된 피리돈 화합물 |
| US10314820B2 (en) | 2014-12-04 | 2019-06-11 | Procomcure Biotech Gmbh | Imidazole-based heterocyclic compounds |
| WO2016087616A1 (en) * | 2014-12-04 | 2016-06-09 | Procomcure Biotech Gmbh | Imidazole-based antimicrobial agents |
| WO2016133793A1 (en) * | 2015-02-16 | 2016-08-25 | Merck Sharp & Dohme Corp. | FACTOR IXa INHIBITORS |
| AU2016224974B2 (en) | 2015-02-27 | 2019-09-26 | Verseon Corporation | Substituted pyrazole compounds as serine protease inhibitors |
| KR20180132783A (ko) * | 2016-04-07 | 2018-12-12 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 단백질 조절제로서 유용한 헤테로사이클릭 아미드 |
| CN113549110B (zh) * | 2016-04-07 | 2024-08-16 | 葛兰素史密斯克莱知识产权发展有限公司 | 用作蛋白质调节剂的杂环酰胺 |
| EP3541381B1 (en) * | 2016-11-18 | 2022-12-28 | Merck Sharp & Dohme LLC | Inhibitors of factor xiia |
| WO2018175670A1 (en) | 2017-03-22 | 2018-09-27 | The Research Foundation For The State University Of New York | Matrix metalloproteinase-9 hemopexin domain inhibitors and methods of treatment using same |
| WO2019204447A1 (en) | 2018-04-17 | 2019-10-24 | The Regents Of The University Of Michigan | Inhibitors of platelet function and methods for use of the same |
| CN112457308B (zh) * | 2019-09-09 | 2024-01-02 | 上海长森药业有限公司 | 新型三环芳香杂环化合物，及其制备方法、药物组合物和应用 |
| EP4143183B1 (en) | 2020-04-29 | 2025-10-22 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2022028572A1 (en) | 2020-08-06 | 2022-02-10 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2022081573A1 (en) * | 2020-10-12 | 2022-04-21 | University Of Tennessee Research Foundation | Transient receptor potential canonical 3 inhibitors and methods of use thereof |
| CN116547279A (zh) * | 2020-10-13 | 2023-08-04 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| CN114149371B (zh) * | 2021-11-26 | 2023-08-22 | 首都医科大学 | 四取代吡唑类化合物及其应用 |
| CN114478511B (zh) * | 2022-02-24 | 2023-06-20 | 中国药科大学 | 苯并恶唑类化合物及其制备方法、药物组合物和应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0028489B1 (en) | 1979-11-05 | 1983-10-05 | Beecham Group Plc | Enzyme derivatives, and their preparation |
| IL106197A (en) | 1992-07-30 | 1999-11-30 | Cor Therapeutics Inc | Agagonists for the rhombin receptors and pharmaceutical preparations containing them |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| US6063847A (en) | 1997-11-25 | 2000-05-16 | Schering Corporation | Thrombin receptor antagonists |
| PT1094816E (pt) | 1998-07-06 | 2009-03-10 | Bristol Myers Squibb Co | Sulfonamidas bifenílicas duplamente antagonistas receptores de angiotensina e endotelina |
| MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| AU6690001A (en) | 2000-06-15 | 2001-12-24 | Schering Corp | Thrombin receptor antagonists |
| US7235567B2 (en) | 2000-06-15 | 2007-06-26 | Schering Corporation | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist |
| KR100960170B1 (ko) | 2001-10-18 | 2010-05-26 | 쉐링 코포레이션 | 트롬빈 수용체 길항제로서의 힘바신 동족체 |
| JP5039268B2 (ja) * | 2001-10-26 | 2012-10-03 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用 |
| JP4558331B2 (ja) | 2002-04-16 | 2010-10-06 | シェーリング コーポレイション | 三環式トロンビンレセプターアンタゴニスト |
| WO2005030128A2 (en) * | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Pyrazole modulators of metabotropic glutamate receptors |
| JP2008505905A (ja) * | 2004-07-07 | 2008-02-28 | メルク エンド カムパニー インコーポレーテッド | ピラゾールアミド誘導体、こうした化合物を含有する組成物および使用方法 |
| CA2574147A1 (en) * | 2004-07-22 | 2006-02-09 | Linda Brockunier | Substituted pyrazoles, compositions containing such compounds and methods of use |
| US8710038B2 (en) * | 2004-09-17 | 2014-04-29 | Exelixis, Inc. | Pyrazole kinase modulators and methods of use |
| US20070197532A1 (en) * | 2005-11-18 | 2007-08-23 | Cao Sheldon X | Glucokinase activators |
| US7968683B1 (en) * | 2008-05-07 | 2011-06-28 | Schering Corporation | Factor IXa crystals, related complexes and methods |
| CA2724294A1 (en) * | 2008-05-16 | 2009-11-19 | Schering Corporation | Glucagon receptor antagonists, compositions, and methods for their use |
-
2009
- 2009-05-18 CN CN200980128238XA patent/CN102099340A/zh active Pending
- 2009-05-18 CA CA2724430A patent/CA2724430A1/en not_active Abandoned
- 2009-05-18 TW TW098116429A patent/TW201008930A/zh unknown
- 2009-05-18 CL CL2009001214A patent/CL2009001214A1/es unknown
- 2009-05-18 JP JP2011510610A patent/JP5504259B2/ja not_active Expired - Fee Related
- 2009-05-18 PE PE2009000694A patent/PE20091972A1/es not_active Application Discontinuation
- 2009-05-18 MX MX2010012635A patent/MX2010012635A/es active IP Right Grant
- 2009-05-18 AR ARP090101778A patent/AR071823A1/es not_active Application Discontinuation
- 2009-05-18 EP EP09751268A patent/EP2300435A2/en not_active Ceased
- 2009-05-18 WO PCT/US2009/044291 patent/WO2009143039A2/en not_active Ceased
- 2009-05-18 US US12/993,607 patent/US8148363B2/en active Active
- 2009-05-18 EP EP14173412.9A patent/EP2805939B1/en not_active Not-in-force
Also Published As
| Publication number | Publication date |
|---|---|
| EP2805939B1 (en) | 2018-06-27 |
| CA2724430A1 (en) | 2009-11-26 |
| JP2011520967A (ja) | 2011-07-21 |
| CL2009001214A1 (es) | 2010-12-31 |
| EP2805939A1 (en) | 2014-11-26 |
| CN102099340A (zh) | 2011-06-15 |
| US8148363B2 (en) | 2012-04-03 |
| PE20091972A1 (es) | 2010-01-15 |
| WO2009143039A2 (en) | 2009-11-26 |
| WO2009143039A3 (en) | 2010-07-08 |
| MX2010012635A (es) | 2010-12-06 |
| AR071823A1 (es) | 2010-07-14 |
| US20110065682A1 (en) | 2011-03-17 |
| EP2300435A2 (en) | 2011-03-30 |
| TW201008930A (en) | 2010-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8148363B2 (en) | Heterocyclic compounds as factor IXA inhibitors | |
| US8609676B2 (en) | 4, 5, 6-trisubstituted pyrimidine derivatives as factor IXa inhibitors | |
| JP7579789B2 (ja) | 免疫調節剤、組成物およびその使用方法 | |
| ES2329881T3 (es) | Compuestos que contienen lactama y derivados de los mismos como inhibidores del factor xa. | |
| JP4795336B2 (ja) | 血栓症病態の治療に有用なｐ２ｙ１レセプターのウレアアンタゴニスト | |
| US20040132732A1 (en) | Quinazolinones and derivatives thereof as factor Xa inhibitors | |
| US20040209863A1 (en) | Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors | |
| US20050119266A1 (en) | Pyrrolidine and piperidine derivatives as factor Xa inhibitors | |
| CN109790169A (zh) | 具有作为usp30抑制剂活性的氰基吡咯烷衍生物 | |
| MX2007012712A (es) | Fenil-acetamidas adecuadas como inhibidores de cinasa de proteina. | |
| AU2013276519B2 (en) | 1,3-dihydro-2H-benzimidazol-2-one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents | |
| RS57659B1 (sr) | Makrociklusi sa heterocikličnim p2' grupama kao inhibitori faktora xia | |
| EP3131896B1 (en) | Factor ixa inhibitors | |
| KR20110075010A (ko) | 키나제 억제제로서 유용한 이미다조피리다진카르보니트릴 | |
| CA2648250A1 (en) | Deazapurines useful as inhibitors of janus kinases | |
| CN112521369A (zh) | 用于抑制fasn的化合物及组合物 | |
| CA2681516A1 (en) | Compounds useful as inhibitors of janus kinases | |
| US12371432B2 (en) | Haloallylamine compounds and application thereof | |
| KR20070012384A (ko) | Ｘａ 억제제로서 유용한 신규한 카복스아미드 | |
| JP2005527485A (ja) | 第Ｘａ因子インヒビターとして新規なＮ−［４−（１Ｈ−イミダゾール−１−イル）−２−フルオロフェニル］−３−（トリフルオロメチル）−１Ｈ−ピラゾール−５−カルボキサミド化合物 | |
| CN115894376B (zh) | 一种芳香族酰胺类化合物、药物组合物及其用途 | |
| CN109721613B (zh) | 含季铵离子的大环酰胺化合物及其药物组合物和用途 | |
| KR20250038764A (ko) | Tead 억제제 및 사용 방법 | |
| IL325136A (en) | Pyrazolo-pyrimidinone compounds for use in methods for inhibiting kinase week1 a | |
| HK40053245A (en) | Haloallylamine compounds and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120410 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120410 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131106 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20131107 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140127 |
|
| TRDD | Decision of grant or rejection written | ||
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20140214 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140217 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140317 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5504259 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D04 |
|
| LAPS | Cancellation because of no payment of annual fees |